Ajanta Pharma Q2 Review: Stock Rally Limits Upside Despite Robust Performance, Says Systematix
NDTV

The brokerage incorporates Ajanta Pharma's quarterly performance into its
estimates and expect India to remain a key growth driver, supported by
sustained outperformance against IPM, while factoring in normalisation in
Africa institutional business.





